Business Context and Reporting Period
The provided filing is DanDrit Biotech USA, Inc.’s Form 10-K, not a filing for Lunai Bioworks Inc. It covers the fiscal year ended June 30, 2017, with comparison to June 30, 2016; it does not provide a separate 2016 fourth-quarter reporting period.
DanDrit is a development-stage biotechnology company with three full-time employees. Its only product is MelCancerVac (MCV), a dendritic-cell cancer vaccine. MCV has been evaluated in Phase I/II and Phase II trials and is available only through compassionate-use programs in Singapore and through the MyTomorrows program. The company has not begun its planned randomized trial involving 174 stage IV colorectal cancer patients.
Key Financial Metrics
| Metric | FY2017 | FY2016 | Change |
|---|---|---|---|
| Net sales | $0 | $42,769 | Down $42,769 |
| Gross profit | $0 | $37,494 | Down $37,494 |
| Operating expenses | $2,650,427 | $2,158,424 | Up 22.8% |
| Operating loss | $(2,650,427) | $(2,120,930) | Loss increased |
| Net loss | $(2,392,830) | $(1,735,239) | Loss increased 37.9% |
| Basic and diluted loss per share | $(0.20) | $(0.18) | Loss per share increased |
| Cash used in operating activities | $(1,177,478) | $(1,472,289) | Use decreased |
| Cash and cash equivalents | $3,941,712 | $23,368 | Substantial increase |
| Working capital | $1,209,461 | $(775,750) | Improved |
| Total assets | $4,522,152 | $870,831 | Increased |
| Total liabilities | $2,989,418 | $1,508,229 | Increased |
FY2017 operating expenses included $1,560,332 of general and administrative expense, $62,763 of research and development expense, $14,528 of depreciation and amortization, and $1,012,804 of consulting expense. The company recorded $192,720 of net other income, primarily from a $218,979 foreign-currency gain.
There was no revenue-based margin in FY2017 because the company recorded no sales. The filing does not provide a meaningful EBITDA measure or a clear debt-to-equity ratio.
Material Changes Versus the Prior Comparable Period
- Sales declined to zero from $42,769 because there were no compassionate-use lysate sales in FY2017.
- Operating expenses increased $492,003, driven primarily by consulting costs, which rose to $1,012,804 from $96,976, and higher legal and administrative expenses.
- Research and development expense declined to $62,763 from $804,188.
- Net loss increased by $657,591 to $2,392,830. The filing attributes the increase primarily to higher operating and consulting expenses and a lower Danish research and development tax benefit.
- Cash improved principally through financing. FY2017 financing cash inflow was $5,506,601, including $3,510,000 from a private placement and proceeds from related-party and convertible notes.
- Shares outstanding increased to 12,433,290 at June 30, 2017 from 9,533,290 a year earlier. Subsequent to year-end, shares outstanding reached 13,727,538 as of September 28, 2017.
Liquidity, Debt, and Financing
- Cash was $3,941,712 at June 30, 2017, although $3,441,711 was held in financial institutions in excess of federally insured amounts.
- Current liabilities totaled $2,989,418, including $1,688,171 of related-party notes payable and $401,673 of related-party convertible notes payable, net of discounts.
- The convertible notes were generally non-interest-bearing, convertible at $2.00 per share, and principally mature on December 31, 2017. The filing identifies $413,670 of related-party convertible notes as short-term debt before discounts.
- The company completed a May 2017 private placement of 2,700,000 shares and warrants to purchase 5,400,000 shares for $3,510,000. On July 12, 2017, it issued an additional 1,231,561 units for $1,601,029.
- On July 14, 2017, the company agreed to lend up to $500,000 to a biopharmaceutical company. $196,140 had been advanced by June 30, 2017; the note bears 5% interest and matures July 13, 2020.
- Management states that additional financing may be required and may be sought through equity or debt offerings. It also states that financing may not be available on acceptable terms or at all.
Outlook, Risks, and Unusual Items
- The company expects to remain dependent on securities sales, loans, and other financing until MCV receives marketing approval. Management states that the company may never become profitable.
- MCV has not been reviewed by the FDA. Prior single-arm clinical-trial data reflect the company’s assessment and do not establish safety, efficacy, or likely success in later-stage trials.
- The planned randomized colorectal cancer trial had not begun, and two related clinical collaboration agreements were terminated in May 2017.
- FDA and foreign regulatory approval is uncertain, costly, and potentially lengthy. Failure or delay in clinical trials or approvals would materially impair potential revenue generation.
- The company faces substantial competition from better-capitalized biotechnology and pharmaceutical companies and has limited commercialization experience.
- Consulting arrangements produced significant unusual and potentially related-party costs. A consultant received $75,000 plus 200,000 shares valued at $490,000, while another consulting arrangement included $5,000 per month plus 100,000 warrants valued at $115,754.
- The company recognized $1,232,241 of non-cash compensation in FY2017, including $626,487 for stock options and $115,754 for consulting warrants.
- Related-party transactions included $268,620 of legal expense to a law firm partially owned by a former chairman and $280,000 of consulting expense to APE Invest, owned by a former director.
- Management determined that disclosure controls and internal control over financial reporting were not effective as of June 30, 2017 because of material weaknesses, inadequate accounting resources, and insufficient segregation of duties.
- The company reports approximately $11.5 million of Danish tax-loss carryforwards and $1.5 million of U.S. tax-loss carryforwards, but a full valuation allowance was recorded because management believes realization is not more likely than not.
- A July 2017 non-binding letter of intent contemplated acquiring a biotechnology company with HIV-related intellectual property; due diligence was ongoing and no completed acquisition was reported.
Most Important Facts to Verify
- Confirm the issuer and reporting period: the supplied document is DanDrit Biotech USA’s FY2017 10-K, not Lunai Bioworks’ 2016 Q4 filing.
- Verify the status, funding, design, and expected timing of the planned 174-patient colorectal cancer trial.
- Reconcile current related-party and convertible debt maturities with available cash and subsequent financing.
- Assess whether the $3.9 million year-end cash balance remains available after subsequent loans, operating losses, and other commitments.
- Review the May and July 2017 equity offerings, warrant dilution, and subsequent share count.
- Investigate the material weaknesses in internal controls and whether corrective actions have been implemented.
- Review related-party consulting, legal, financing, and equity transactions for governance and dilution implications.
- Evaluate the regulatory, clinical, intellectual-property, and product-liability risks before assigning value to MCV.